Selected for the “Manufacturing, Commerce, and Service Productivity Enhancement Subsidy Program”

ProteoBridge Inc. (Head Office: Koto-ku, Tokyo; President & CEO: Ryo Kumagai) is pleased to announce that our business plan has been selected for the “Manufacturing, Commerce, and Service Productivity Enhancement Subsidy Program (20th round)” implemented by the Ministry of Economy, Trade and Industry (METI) and the Small and Medium Enterprise Agency.

The selected project is the development of a novel protein array equipped with a newly discovered rheumatoid arthritis biomarker identified by our company.

Through this development, we aim to advance the provision of research diagnostic tools that contribute to improving diagnostic accuracy in clinical settings, thereby contributing to higher-precision medical care driven by biomarker research.

■ Overview of the Project

Project: Development of A-Cube® Rheumatoid Arthritis Panel for research testing

Selected Program: Manufacturing, Commerce, and Service Productivity Enhancement Subsidy Program (20th round)

Implementing Agency: Small and Medium Enterprise Agency

■ Objectives and Future Outlook

This project aligns closely with Japan’s national health policies, particularly the Ministry of Health, Labour and Welfare’s “Health Japan 21” and the “Smart Life Project,” both of which promote the extension of healthy life expectancy.

Rheumatoid arthritis is a disease in which early diagnosis and early treatment can suppress joint destruction, potentially reducing the long-term use of biologics, surgeries, and rehabilitation, thereby lowering healthcare costs. In addition, smoking is known as a risk factor for disease onset and progression; therefore, combining early detection with lifestyle improvement guidance can help maintain public health and improve QOL.

With the newly developed A-Cube® Rheumatoid Arthritis Panel, we aim to enhance diagnostic accuracy and reduce the number of “seronegative” patients. This will strengthen the pathway to early treatment and promote the widespread adoption of a preventive healthcare model aligned with national health initiatives. Furthermore, we will expand collaborations with medical and research institutions and work to build a comprehensive platform supporting diagnosis, prevention, and lifestyle guidance—ultimately contributing to a sustainable healthcare system.

【About ProteoBridge Inc.】

ProteoBridge Inc. is a biotechnology company dedicated to the early detection of diseases and the realization of personalized medicine through biomarker research and analysis, with a focus on autoantibodies.

Through collaborative development with research institutes and pharmaceutical companies, we strive to create innovative research testing and analytical technologies in the field of autoimmune diseases.

Address: 2-4-7 Aomi, Koto-ku, Tokyo

CEO: Ryo Kumagai

Founded: January 5, 2018